Study protocol: a randomised, controlled trial of a nurse navigator program for the management of hepatitis C virus in patients with severe mental disorder

Casta Quemada-González, José Miguel Morales-Asencio, María M Hurtado, Celia Martí-García, Casta Quemada-González, José Miguel Morales-Asencio, María M Hurtado, Celia Martí-García

Abstract

Background: To evaluate the impact of a nurse navigation program on treatment adherence and resolution of hepatitis C infection in patients with severe mental disorder.

Methods: An open, randomized, controlled trial with blinded outcome assessment. The intervention group will engage in a nurse navigation program designed by mental health nurses. The program involves active screening for patients with severe mental disorder. The patients and caregivers included in the program will receive information, training, support and guidance throughout the treatment and recovery process, which involves different healthcare professionals and units. The control group will receive the standard of care, which includes follow-up by a family physician, referral to the hepatologist, serological testing, new referral to the hepatologist, onset of treatment, and follow-up. Multidisciplinary care will be provided along a coordinated and seamless clinical pathway led by a nurse navigator. The primary endpoints are total recovery (hepatitis C cure) and treatment adherence. Occurrence of symptoms of schizophrenia and health-related quality of life will be also recorded. Follow-up of patients will be performed three and six months after the administration of antiviral treatment. The study was authorised by the Ethics Committee of Malaga in December 2021. Funding was approved in March 2021.

Discussion: If this intervention is proven to be effective in improving treatment access and adherence, it will represent a step forward in addressing a chronic health issue that is 16 times more prevalent in the population with severe mental disease. Finally, this intervention may lead to the detection of undertreated HCV infection in this population of patients.

Trial registration: This protocol has been registered in ClinicalTrials.gov with identifier code NCT04891445 on May 18, 2021.

Keywords: Critical pathways; Hepatitis C; Mental disorders; Nursing; Patient care planning.

Conflict of interest statement

The author Casta Quemada declares that she provided paid services in an occasion, as a speaker in an educational course organised by GILEAD. This project is funded by GILEAD through a competitive research Scholarship.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Clinical route scheme hepatitis C in SMD patient

References

    1. Saxena S, Maj M. Physical health of people with severe mental disorders: leave no one behind. World Psychiatry. 2017;16(1):1–2.
    1. Wahlbeck K, Westman J, Nordentoft M, Gissler M, Laursen T. Outcomes of Nordic mental health systems: life expectancy of patients with mental disorders. Br J Psychiatry. 2011;199(6):453–8.
    1. Hor K, Taylor M. Suicide and schizophrenia: a systematic review of rates and risk factors. J Psychopharmacol. 2010;24(4):81–90.
    1. Ayano G, Tulu M, Haile K, Assefa D, Habtamu Y, Araya G, et al. A systematic review and meta-analysis of gender difference in epidemiology of HIV, hepatitis B, and hepatitis C infections in people with severe mental illness. Ann Gen Psychiatry. 2018;17(1):16.
    1. Hofstraat SHI, Falla AM, Duffell EF, Hahné SJM, Amato-Gauci AJ, Veldhuijzen IK, et al. Current prevalence of chronic hepatitis B and C virus infection in the general population, blood donors and pregnant women in the EU/EEA: a systematic review. Epidemiol Infect. 2017;145(14):2873–85.
    1. Ayano G, Haile K, Tesfaye A, Haile K, Demelash S, Tulu M, et al. Undiagnosed HIV, hepatitis B, and hepatitis C infections in people with severe psychiatric disorders in Ethiopia. BMC Infect Dis. 2020;20(1):180.
    1. Schulze LN, Stentzel U, Leipert J, Schulte J, Langosch J, Freyberger HJ, et al. Improving medication adherence with telemedicine for adults with severe mental illness. PS. 2019;70(3):225–8.
    1. Mohamed ES. Effectiveness of Psychiatric Nursing Intervention on Adherence to Medications and Quality of Life of Schizophrenic Patients. AJNS. 2016;5(6):232.
    1. El-Azzab SI, Abu-Salem EM. Effective strategies for nurses empowering the life quality and antipsychotic adherence of patients with schizophrenia. JNEP. 2018;8(10):106.
    1. Lawrence D, Hancock KJ, Kisely S. The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers. BMJ. 2013;346(1):f2539.
    1. Brown AS, Patterson PH. Maternal infection and schizophrenia: implications for prevention. Schizophr Bull. 2011;37(2):284–90.
    1. National Institute for Health and Care Excellence (NICE). Psychosis and Schizophrenia in adults. The NICE guideline of treatment and management. Vol. Guideline Number 178. London; 2014. p. 39.
    1. García-Herrera Pérez Bryan JM, Hurtado Lara MM, Quemada González C, Nogueras Morillas E, Bordallo Aragón A, Martí García C. In: Guía de Práctica Clínica para el Tratamiento de la Psicosis y la Esquizofrenia [ClinicalGuidelines for the treatment of psychoses and schizophrenia] 1. de Salud Servicio Andaluz., editor. Sevilla: The Andalusian Public Health System; 2019. p. 719.
    1. Ribe AR, Vestergaard M, Katon W, Charles M, Benros ME, Vanderlip E, et al. Thirty-day mortality after infection among persons with severe mental illness: a population-based cohort study in Denmark. AJP. 2015;172(8):776–83.
    1. Karabulut N. Prevalence of HBV, HCV and HIV in inpatients of a mental health hospital in Turkey, 2011–2013. Iran J Public Health. 2015;44(7):1026–8.
    1. Nielsen PR, Laursen TM, Agerbo E. Comorbidity of schizophrenia and infection: a population-based cohort study. Soc Psychiatry Psychiatr Epidemiol. 2016;51(12):1581–9.
    1. Bauer-Staeb C, Jörgensen L, Lewis G, Dalman C, Osborn DPJ, Hayes JF. Prevalence and risk factors for HIV, hepatitis B, and hepatitis C in people with severe mental illness: a total population study of Sweden. Lancet Psychiatry. 2017;4(9):685–93.
    1. Gunewardene R, Lampe L, Ilchef R. Prevalence of hepatitis C in two inpatient psychiatry populations. Australas Psychiatry. 2010;18(4):330–4.
    1. Nikoo N, Javidanbardan S, Akm M, Hakobyan S, Nikoo M, Kwan C, et al. Hepatitis C prevalence and associated risk factors among individuals who are homeless and diagnosed with mental illness: At Home/Chez Soi Study, Vancouver BC. Eur J Public Health. 2019;29(2):242–7.
    1. Yeoh SW, Holmes ACN, Saling MM, Everall IP, Nicoll AJ. Depression, fatigue and neurocognitive deficits in chronic hepatitis C. Hepatol Int julio de. 2018;12(4):294–304.
    1. Hsiao P, Hsieh P, Chou E, Lai H, Peng C, Su K. Anti-Viral Therapy and Decreased Sexual Desire in Patients with Chronic Hepatitis C. PloS one. 2016;11(8):e0160450.
    1. Juengling FD, Ebert D, Gut O, Engelbrecht MA, Rasenack J, Nitzsche EU, et al. Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacol. 2000;152(4):383–9.
    1. Neri S, Pulvirenti D, Bertino G. Psychiatric symptoms induced by antiviral therapy in chronic hepatitis C: comparison between interferon-2a and interferon-2b. Clin Drug Investig. 2006;26(11):655–62.
    1. Raison CL, Rye DB, Woolwine BJ, Vogt GJ, Bautista BM, Spivey JR, et al. Chronic interferon-alpha administration disrupts sleep continuity and depth in patients with hepatitis C: association with fatigue, motor slowing, and increased evening cortisol. Biol Psychiatry. 2010;68(10):942–9.
    1. Pawelczyk T, Pawelczyk A, Strzelecki D, Rabe-Jablonska J. Pegylated interferon α and ribavirin therapy may induce working memory disturbances in chronic hepatitis C patients. Gen Hosp Psychiatry. 2008;30(6):501–8.
    1. Feld JJ, Maan R, Zeuzem S, Kuo A, Nelson DR, Di Bisceglie AM, et al. Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study. Clin Infect Dis. 2016;63(6):776–83.
    1. Nielsen R, Kugathasan P, Straszek S, Jensen S, Licht R. Why are somatic diseases in bipolar disorder insufficiently treated? Int J Bipolar Disord. 2019;7(1):12.
    1. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RIG, Möller H-J. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatr. 2009;24(6):412–24.
    1. Ameel M, Kontio R, Välimäki M. Interventions delivered by nurses in adult outpatient psychiatric care: An integrative review. J Psychiatr Ment Health Nurs. 2019;26(9–10):301–22.
    1. Mahone IH, Maphis CF, Snow DE. Effective strategies for nurses empowering clients with schizophrenia: medication use as a tool in recovery. Issues Ment Health Nurs. 2016;37(5):372–9.
    1. Pinheiro CW, Araújo MÂM, Rolim KMC, De Oliveira CM, De Alencar AB. Teoria das relações interpessoais: reflexões acerca da função terapêutica do enfermeiro em saúde mental. revenf [Internet]. 2019;10(3). Available in: .
    1. Virgolesi M, Pucciarelli G, Colantoni AM, D’Andrea F, Di Donato B, Giorgi F, et al. The effectiveness of a nursing discharge programme to improve medication adherence and patient satisfaction in the psychiatric intensive care unit. J Clin Nurs. 2017;26(23–24):4456–66.
    1. Goodyear T, Ti L, Carrieri P, Small W, Knight R. “Everybody living with a chronic disease is entitled to be cured”: Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs. Int J Drug Policy. 2020;81:102766.
    1. Kim JY, Higgins TC, Esposito D, Hamblin A. Integrating health care for high-need medicaid beneficiaries with serious mental illness and chronic physical health conditions at managed care, provider, and consumer levels. Psychiatr Rehabil J. 2017;40(2):207–15.
    1. Happell B, Wilson K, Platania-Phung C, Stanton R. Physical health nurse consultant role to improve physical health in mental health services: A carer’s perspective: Physical Health Nurse Consultant. Int J Mental Health Nurs. 2016;25(3):243–50.
    1. Ryvicker M. A conceptual framework for examining healthcare access and navigation: a behavioral-ecological perspective. Soc Theory Health. 2018;16(3):224–240.
    1. Happell B, Scott D, Platania-Phung C. Perceptions of barriers to physical health care for people with serious mental illness: a review of the international literature. Issues Ment Health Nurs. 2012;33(11):752–61.
    1. Kreyenbuhl J, Dixon LB, McCarthy JF, Soliman S, Ignacio RV, Valenstein M. Does adherence to medications for type 2 diabetes differ between individuals with vs without schizophrenia? Schizophr Bull. 2010;36(2):428–35.
    1. Ho CJ, Preston C, Fredericks K, Doorley SL, Kramer RJ, Kwan L, et al. A unique model for treating chronic hepatitis C in patients with psychiatric disorders, substance abuse, and/or housing instability. J Addict Med. 2013;7(5):320–4.
    1. Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG Adherence Instruments. AIDS Care. 2000;12(3):255–266.
    1. Badiee J, Riggs PK, Rooney AS, Vaida F, Grant I, Atkinson JH, et al. Approaches to identifying appropriate medication adherence assessments for HIV infected individuals with comorbid bipolar disorder. AIDS Patient Care STDs. 2012;26(7):388–94.
    1. Bulbena Vilarrasa A, Fernández de Larrinoa Palacios P, Domínguez Panchón AI. Adaptación castellana de la escala LSP (Life Skills Profile). Perfil de habilidades de la vida cotidiana. Estructura y composición factorial [Castillian adaptation of the LSP (Life Skills Profile): profile of the skills employed in daily living: structure and factorial composition]. Actas Luso Esp de Neurol Psiquiatr Cienc Afines. 1992;20(2):51–60.
    1. Peralta V, Cuesta MJ. Psychometric properties of the Positive and Negative Syndrome Scale (PANSS) in schizophrenia. Psychiatry Res. 1994;53(1):31–40.
    1. Herdman M, Badia X, Berra S. El EuroQol-5D: una alternativa sencilla para la medición de la calidad de vida relacionada con la salud en atención primaria. Aten Prim. 2001;28(6):425–9.
    1. Badia X, Roset M, Montserrat S, Herdman M, Segura A. The Spanish version of EuroQol: description and applications. Med Clin (Barc). 1999;112:79–85.
    1. Rebollo P, Morís J, Ortega T, Valdés C, Ortega F. Estimating utility values for health status using the Spanish version of the SF-36. Validity of the SF-6D index vs EQ-5D. Med Clin (Barc). 2007;128(14):536–7. 10.1157/13101163.
    1. Boglione L, Lupia T, Cariti G, Di Perri G. Efficacy and safety of interferon-free regimens in patients affected by chronic hepatitis C and psychiatric disorders. J Infection Chemotherapy. 2020;26(1):18–22.
    1. Lluch E, Miller BJ. Rates of hepatitis B and C in patients with schizophrenia: a meta-analysis. Gen Hosp Psychiatry. 2019;61:41–6.
    1. Chasser Y, Kim AY, Freudenreich O. Hepatitis C treatment: clinical issues for psychiatrists in the post-interferon era. Psychosomatics. 2017;58(1):1–10.
    1. Gur S, Weizman S, Stubbs B, Matalon A, Meyerovitch J, Hermesh H, et al. Mortality, morbidity and medical resources utilization of patients with schizophrenia: a case-control community-based study. Psychiatry Res. 2018;260:177–81.
    1. Park A-L, McDaid D, Weiser P, Von Gottberg C, Becker T, Kilian R. Examining the cost effectiveness of interventions to promote the physical health of people with mental health problems: a systematic review. BMC Public Health. 2013;13(1):787.
    1. Kim J, Ozzoude M, Nakajima S, Shah P, Caravaggio F, Iwata Y, et al. Insight and medication adherence in schizophrenia: An analysis of the CATIE trial. Neuropharmacol. 2020;168:107634.
    1. Phan SV. Medication adherence in patients with schizophrenia. Int J Psychiatry Med. 2016;51(2):211–9.
    1. Hurtado MM, Triviño M, Arnedo M, Roldán G, Tudela P. Are executive functions related to emotional intelligence? A correlational study in schizophrenia and borderline personality disorder. Psychiatry Res. 2016;246:84–8.
    1. Thuaire F, Rondepierre F, Vallet GT, Jalenques I, Izaute M. Executive deficits in schizophrenia: mediation by processing speed and its relationships with aging. Psychol Med. 2020;1–9. 10.1017/S0033291720002871.
    1. Daumit GL, Dalcin AT, Dickerson FB, Miller ER, Evins AE, Cather C, et al. Effect of a Comprehensive Cardiovascular Risk Reduction Intervention in Persons With Serious Mental Illness: A Randomized Clinical Trial. JAMA Netw Open. 2020;3(6):e207247.
    1. Meepring S, Chien WT, Gray R, Bressington D. Effects of the Thai Health Improvement Profile intervention on the physical health and health behaviours of people with schizophrenia: A quasi-experimental study. Int J Mental Health Nurs. 2018;27(1):126–37.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する